Phase 3 trial to assess M72/AS01E-4 Mycobacterium tuberculosis (TB) vaccine (360G-Wellcome-227209_Z_23_Z)
Funding Organisation
£125,955,160
Recipient Organisation
A Phase 3, randomized, observer-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0-,1-month schedule to adolescents and adults.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2023-09-30T00:00:00+00:00 |
| Internal ID | 227209/Z/23/Z |
| Planned Dates: End Date | 2033-01-12T00:00:00+00:00 |
| Planned Dates: Start Date | 2023-01-13T00:00:00+00:00 |
| Amount Awarded | 125955159.97 |
| Financial Year | 2022/23 |
| Lead Applicant | PATRICE MATCHABA |
| Grant Programme: Title | Discretionary Award |
| Applicant Surname | MATCHABA |
| Approval Committee | Internal Decision Panel |
| Recipient Org: Country | United States |
| Recipient Org: City | Cambridge |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | No |
| Total amount including partnership funding | 125955159.97 |